Leucid Bio

Executive Summary

Leucid Bio is a clinical-stage biotechnology company based in London, UK, pioneering next-generation CAR-T cell therapies for refractory cancers. The company's proprietary Lateral CAR platform re-engineers the CAR structure to mimic natural immune receptor signaling, potentially improving persistence and efficacy in solid tumors. Its lead candidate, LEU011, is an autologous CAR-T therapy targeting NKG2D ligands and is currently in early clinical trials. The company's innovative approach aims to overcome key limitations of conventional CAR-T cells, such as antigen escape and immunosuppressive tumor microenvironments. With a strong focus on solid tumors, Leucid Bio represents a promising player in the cell therapy space, though it operates in a competitive landscape with several large and small biotech firms developing similar technologies.

Upcoming Catalysts (preview)

• TBDInitial Phase 1 clinical data readout for LEU011 in solid tumors40% success
• TBDPotential partnership or licensing deal for Lateral CAR platform30% success
• TBDSeries A or B financing round to support further clinical development50% success